Hospital

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

The results of 3 phase 3 trials showed that the drug offered greater proportions of individuals with the condition who met the endpoints of clinical remission and endoscopic response.

With the recent announcement of federal COVID-19 vaccine mandates, in addition to private businesses potentially requiring vaccines for employees, pharmacies and other health care facilities could have questions about legal issues surrounding these mandates.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

Trial results showed a 24% confirmed objective response rate with a median duration of response of 8.3 months among patients with cervical cancer who received tisotumab vedotin-tftv.

Relatlimab is the first LAG-3-blocking antibody to demonstrate a clinical benefit for patients with melanoma in phase 3 data.

Phase 3 trial results show that the drug reduced the risk of death or reoccurrence by 35% for individuals with high-risk disease compared with the placebo.

Nearly 94.1% of individuals treated with the drug in the DESTINY-Breast03 study were still alive at the 1-year mark, according to a statement from AstraZeneca.

Cisplatin is frequently an effective therapy for pediatric cancer, but it is also known to cause permanent hearing loss in some patients.

In a phase 3 trial, the medication significantly reduced the risk of disease progression compared with individuals in a placebo group.

Sophia Humphreys, PharmD, MHA, said data are continuing to evolve around the safety and recommendations of COVID-19 booster doses, especially for the vaccine from Pfizer and BioNTech.

There are 4 essential epidermal growth factor receptor-mutant non-small cell lung cancer subgroups, according to new research results.

Pharmacists will need to make sure they have the necessary personal protective equipment in place to meet increased clinic activity and while keeping an eye on levels of flu vaccines and tests.

REMS are not intended to minimize all harmful effects of a drug, but instead focus on preventing, tracking, and handling a specific serious risk by informing, educating, and/or enforcing measures that reduce the frequency and/or intensity of the event.

Integrating these facilities into the pharmacy supply chain strategy has become key for hospitals during the pandemic.

Apalutamide (Erleada, Johnson & Johnson) demonstrated a strong prostate-specific antigen response and high adherence rates in patients with non-metastatic castration-resistant prostate cancer.

Schedule I drugs, substances, or chemicals are defined as medications with no currently accepted medical use and a high potential for abuse.

The panel did, however, vote to recommend the booster shots to adults over 65 years of age and those at high risk of severe COVID-19.

A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma.

Shereen Stutz and Mark Alwardt, of McKesson, said the rise in oral oncolytics during the COVID-19 pandemic allowed pharmacists to be more innovative and to become an even more integrated part of the oncology care team.

PrEP simplifies management of the virus by eliminating the need for immune globulin and decreasing the number of doses needed.

Strong immune memory lasted in all age groups tested after receiving the Moderna vaccine, including individuals over 70 years of age who are especially vulnerable to COVID-19.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

Clinical trial results found a 30% reduction in the risk of death and a 2.3-month extension in median overall survival among patients with advanced or metastatic esophageal squamous cell carcinoma treated with tislelizumab.

The FDA approved Exkivity to treat non-small cell lung cancer along with Thermo Fisher Scientific’s Oncomine DX Target Test, which is intended to be a companion diagnostic for the treatment.

Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-based regimens.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.